InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332 ...Middle East

BEIJING, Aug. 15, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced today the first subject dosed in clinical trial of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 in China....

Hence then, the article about innocare announces first subject dosed in clinical trial of icp 332 was published today ( Monday 16/08/2021 - 05:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332 )

Also on site :

• Trump endorses Steven Hilton in California governor's race
• I Asked Dietitians What Women Over 50 Are Getting Wrong About Their Diets, and They All Said the Same 2 Things
• This 1954 Film Ranked as Alfred Hitchcock's No. 1 'Masterpiece'